[A25-64] Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V
Last updated 15.08.2025
Project no.:
A25-64
Commission:
Commission awarded on 14.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified who are ineligible for autologous stem cell transplant
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-64
| Project no. | Title | Status |
|---|---|---|
| G23-17 | Glofitamab (diffuse large B-cell lymphoma) – Assessment according to § 35a Social Code Book (SGB) V (1) Sentence 11 | Commission completed |
| A25-65 | Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V | Commission completed |